Skip to content
Screener

Maze Therapeutics MAZE Price / book

Price / book at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
6.2×-0.5×
Septerna, Inc. logo
Septerna, Inc.SEPN
3.9×+2.6×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
4.9×+3.8×
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
2.7×+2.0×
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
4.6×+2.9×
Schrodinger logo
SchrodingerSDGR
3.7×-0.7×

Other financials

Income statement

See full
Revenue$20.0M—
Operating income-$48.0M-31.7%
Net income-$44.7M-32.8%
EPS (diluted)-$0.76+1.3%

Balance sheet

See full
Cash & equivalents$202.6M-23.4%
Total debt$60.4M+142%
Total equity$453.1M+72.8%
Total assets$531.6M+75.2%

Cash flow

See full
Operating cash flow-$15.1M+49.9%
CapEx$107.0K-72.8%
Free cash flow-$15.2M+50.2%

Valuation

See full
Market cap$1.51B+156%
Enterprise value$1.37B+290%

Returns & leverage

See full
Return on equity-37.3%—
Debt / equity0.1×0.0×
Current ratio18.3×+4.7×

Where this comes from

Calculated from Maze Therapeutics’s reported figures.

market cap/total stockholders equity=3.6×

Based on the most recent quarter.

The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:48 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344903

FAQ

What is Maze Therapeutics's price / book?
Maze Therapeutics (MAZE) reported price / book of 3.6× in Q2 2026.
How has Maze Therapeutics's price / book changed year-over-year?
Maze Therapeutics's price / book increased by 111.3% year-over-year, from 1.7× to 3.6×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Maze Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude